Recently, sotatercept, an activin ligand trap capable of reducing TGFβ/activin signaling, improved exercise capacity in PAH patients and was recently approved for the treatment of PAH [8]. This evidence concerns the gene TGFB1 and pulmonary arterial hypertension.